共 50 条
- [11] THE REAL-WORLD OBSERVATIONAL PROSPECTIVE STUDY OF HEALTH OUTCOMES WITH DULAGLUTIDE & LIRAGLUTIDE IN TYPE 2 DIABETES PATIENTS (TROPHIES): 6-MONTH ANALYSIS RESULTSVALUE IN HEALTH, 2020, 23 : S506 - S506Giorgino, F.Guerci, B.Garcia-Perez, L. E.Boye, K.Aigner, U.Heitmann, E.Federici, Orsini M.Zimner-Rapuch, S.Rosilio, M.Norrbacka, K.Sapin, H.
- [12] The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Patients with Type 2 Diabetes (TROPHIES): Patient disposition, clinical characteristics and treatment persistence at 12 monthsDIABETES OBESITY & METABOLISM, 2022, 24 (12): : 2373 - 2382Guerci, BrunoGiorgino, FrancescoSapin, HeleneBoye, KristinaLebrec, JeremieFederici, Marco OrsiniHeitmann, ElkeDib, AnneFuchtenbusch, MartinGarcia-Perez, Luis-Emilio
- [13] The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES) : Final 24-Month Primary Endpoint AnalysisDIABETES, 2022, 71Giorgino, FrancescoGuerci, BrunoGarcia-Perez, Luis-EmilioFuechtenbusch, MartinLebrec, JeremieFederici, Marco OrsiniDib, AnneHeitmann, ElkeYu, MariaBoye, Kristina
- [14] The real-world observational prospective study of health outcomes with dulaglutide and liraglutide in type 2 diabetes patients (TROPHIES): resource use and costs of treatment in clinical practice in France, Germany, and ItalyJOURNAL OF MEDICAL ECONOMICS, 2024, 27 (01) : 866 - 879Barrett, AnnabelBoye, Kristina S.Garcia-Perez, Luis-EmilioGiorgino, FrancescoGuerci, BrunoFuchtenbusch, MartinYu, MariaSapin, HeleneDib, AnneHeitmann, ElkeFederici, Marco OrsiniLebrec, Jeremie
- [15] The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES) : Final 24-Month Clinical Characteristics and Treatment Pattern AnalysesDIABETES, 2022, 71Guerci, BrunoGiorgino, FrancescoBoye, KristinaFuechtenbusch, MartinHeitmann, ElkeLebrec, JeremieDib, AnneFederici, Marco OrsiniYu, MariaGarcia-Perez, Luis-Emilio
- [16] The real-world observational prospective study of health outcomes with dulaglutide and liraglutide in patients with type 2 diabetes (TROPHIES): Final, 24-month analysis of time to first significant treatment change, treatment persistence and clinical outcomesDIABETES OBESITY & METABOLISM, 2023, 25 (12): : 3465 - 3477Giorgino, FrancescoGuerci, BrunoFuechtenbusch, MartinLebrec, JeremieBoye, KristinaFederici, Marco OrsiniHeitmann, ElkeDib, AnneYu, MariaSapin, HeleneGarcia-Perez, Luis-Emilio
- [17] The real-world observational prospective study of health outcomes with dula and liraglutide in type 2 diabetes patients (TROPHIES): 24-m clinical characteristics and treatment patternsDIABETOLOGIA, 2022, 65 (SUPPL 1) : S315 - S316Dib, A.Guerci, B.Giorgino, F.Boye, K.Fuchtenbusch, M.Heitmann, E.Lebrec, J.Federici, M. OrsiniYu, M.Garcia-Perez, L. -E.
- [18] Real-world effectiveness of liraglutide versus dulaglutide in Japanese patients with type 2 diabetes: a retrospective studyScientific Reports, 12Kenichi TanakaYosuke OkadaAkemi TokutsuYoshiya Tanaka
- [19] Real-world effectiveness of liraglutide versus dulaglutide in Japanese patients with type 2 diabetes: a retrospective studySCIENTIFIC REPORTS, 2022, 12 (01)Tanaka, KenichiOkada, YosukeTokutsu, AkemiTanaka, Yoshiya
- [20] A real-world analysis of global patient-reported outcomes in patients with migraineJOURNAL OF HEADACHE AND PAIN, 2018, 19Ford, Janet H.Cotton, SarahJackson, JamesAndrews, Jeffrey S.Foster, Shonda A.Ye, WenyuNichols, Russell M.Tockhorn-Heidenreich, Antje